Proteomics

Dataset Information

0

LC-MS/MS analyses of human PDAC cell lines after treatment with a new SUMO inhibitor


ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with overall five-year survival of 8%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC, however subtypes of the disease exist, which exhibit extensive resistance to such therapies. Genomic MYC amplifications represent a distinct subset of PDAC with an aggressive tumor biology. It is clear that hyperactivation of MYC generates dependencies that can be exploited therapeutically. To find MYC-associated dependencies we analyzed human PDAC expression datasets. We observed that MYC is connected to the SUMOylation machinery in PDAC. Components of the SUMO pathway mark a PDAC subtype with worse prognosis and we provide evidence that hyperactivation of MYC is connected to an increased sensitivity to a novel SUMO inhibitor with a potential for further clinical development.

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Pancreatic Ductal Adenocarcinoma Cell, Permanent Cell Line Cell, Cell Culture

DISEASE(S): Pancreatic Ductal Adenocarcinoma

SUBMITTER: Kathrin Schunck  

LAB HEAD: Prof. Dr. Ulrich Keller

PROVIDER: PXD011347 | Pride | 2020-01-06

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
20180316_GT_KK_Ex238_1.raw Raw
20180316_GT_KK_Ex238_10.raw Raw
20180316_GT_KK_Ex238_11.raw Raw
20180316_GT_KK_Ex238_12.raw Raw
20180316_GT_KK_Ex238_13.raw Raw
Items per page:
1 - 5 of 31

Similar Datasets

2019-01-01 | GSE119423 | GEO
2011-12-08 | E-GEOD-34055 | biostudies-arrayexpress
2024-06-01 | GSE216091 | GEO
2024-06-01 | GSE216090 | GEO
2024-06-01 | GSE264280 | GEO
2024-06-01 | GSE216095 | GEO
2024-06-01 | GSE216092 | GEO
2015-09-03 | E-GEOD-66182 | biostudies-arrayexpress
2016-04-01 | E-GEOD-79504 | biostudies-arrayexpress
2016-04-01 | E-GEOD-79503 | biostudies-arrayexpress